AbbVie Inc.
ABBVAPI behind this page
ABBV Q3 2025 request
Playground key active
/api/financials?ticker=ABBV&year=2025&quarter=3
Pick an endpoint and run the request.Income Statement
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Revenue | 15,776 | 14,460 | +9.1% |
| Cost of Revenue | 5,304 | 4,212 | +25.9% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest · Foreign Exchange Forward | -41 | -19 | -115.8% |
| Selling, General & Administrative | 3,569 | 4,205 | -15.1% |
| Research And Development Expense Excluding Acquired In Process Cost | 2,319 | 2,130 | +8.9% |
| Research And Development Asset Acquired Other Than Through Business Combination Written Off | 2,680 | 82 | +3168.3% |
Show Counterparty Name breakouts |
|||
| Capstan Therapeutics, Inc. | 1.9 | — | — |
| Ichnos Glenmark Innovation, Inc. | 700 | — | — |
| Other Collaboration Arrangements · Collaborative Arrangement | 2,615 | 82 | +3089.0% |
| Total Costs & Expenses | 13,872 | 10,629 | +30.5% |
| Operating Income | 1,904 | 3,831 | -50.3% |
| Interest Income Expense Nonoperating Net | 667 | 591 | +12.9% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest · Treasury Lock | -5 | -6 | +16.7% |
| Aoci Derivative Qualifying As Hedge Excluded Component Parent · Net Investment Hedging | -37 | -32 | -15.6% |
| Foreign Currency Transaction Gain Loss Before Tax | 20 | -3 | +766.7% |
| Other Non-Operating Income (Expense) | 503 | 1,159 | -56.6% |
| Income Before Taxes | 714 | 2,084 | -65.7% |
| Income Tax Expense (Benefit) | 526 | 520 | +1.2% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest · Reclassification Out Of Accumulated Other Comprehensive Income | 8 | 5 | +60.0% |
| Aoci Derivative Qualifying As Hedge Excluded Component Parent · Net Investment Hedging | 8 | 7 | +14.3% |
| Net Income | 188 | 1,564 | -88.0% |
| Net Income Loss Attributable To Noncontrolling Interest | 2 | 3 | -33.3% |
| Net Income | 186 | 1,561 | -88.1% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest · Reclassification Out Of Accumulated Other Comprehensive Income | 38 | 20 | +90.0% |
| Aoci Derivative Qualifying As Hedge Excluded Component Parent · Net Investment Hedging | 29 | 25 | +16.0% |
| Retained Earnings | 186 | 1,561 | -88.1% |
| EPS (Basic) | 0.1 | 0.88 | -88.6% |
| EPS (Diluted) | 0.1 | 0.88 | -88.6% |
| Wtd Avg Shares (Basic) | 1,769 | 1,769 | 0.0% |
| Wtd Avg Shares (Diluted) | 1,772 | 1,772 | 0.0% |
| Revenue (Q) | — | — | — |
Show Product Lines breakouts |
|||
| All other | 660 | 726 | -9.1% |
| Alphagan/Combigan · Eye Care | 47 | 62 | -24.2% |
| Alphagan/Combigan · Non Us | 38 | 36 | +5.6% |
| Alphagan/Combigan · US | 9 | 26 | -65.4% |
| Botox Cosmetic · Aesthetics | 637 | 671 | -5.1% |
| Botox Cosmetic · Non Us | 258 | 257 | +0.4% |
| Botox Cosmetic · US | 379 | 414 | -8.5% |
| Botox Therapeutic · Neuroscience | 985 | 848 | +16.2% |
| Botox Therapeutic · Non Us | 160 | 140 | +14.3% |
| Botox Therapeutic · US | 825 | 708 | +16.5% |
| Creon · US | 368 | 338 | +8.9% |
| Duodopa · Neuroscience | 96 | 111 | -13.5% |
| Duodopa · Non Us | 80 | 87 | -8.0% |
| Duodopa · US | 16 | 24 | -33.3% |
| Elahere · Non Us | 20 | — | — |
| Elahere · Oncology | 170 | 139 | +22.3% |
| Elahere · US | 150 | 139 | +7.9% |
| Epkinly · Non Us | 25 | 12 | +108.3% |
| Epkinly · Oncology | 69 | 43 | +60.5% |
| Humira · Immunology | 993 | 2,227 | -55.4% |
| Humira · Non Us | 374 | 462 | -19.0% |
| Humira · US | 619 | 1,765 | -64.9% |
| Imbruvica · Oncology | 706 | 828 | -14.7% |
| Imbruvica · US | 507 | 618 | -18.0% |
| Juvederm Collection · Aesthetics | 253 | 258 | -1.9% |
| Juvederm Collection · Non Us | 155 | 153 | +1.3% |
| Juvederm Collection · US | 98 | 105 | -6.7% |
| Linzess/Constella · Non Us | 11 | 9 | +22.2% |
| Linzess/Constella · Other Key Products | 326 | 234 | +39.3% |
| Linzess/Constella · US | 315 | 225 | +40.0% |
| Lumigan/Ganfort · Eye Care | 97 | 116 | -16.4% |
| Lumigan/Ganfort · Non Us | 55 | 58 | -5.2% |
| Lumigan/Ganfort · US | 42 | 58 | -27.6% |
| Mavyret · Non Us | 166 | 155 | +7.1% |
| Mavyret · Other Key Products | 312 | 302 | +3.3% |
| Mavyret · US | 146 | 147 | -0.7% |
| Other Aesthetics · Aesthetics | 303 | 310 | -2.3% |
| Other Aesthetics · Non Us | 38 | 38 | 0.0% |
| Other Aesthetics · US | 265 | 272 | -2.6% |
| Other Eye Care · Eye Care | 248 | 228 | +8.8% |
| Other Eye Care · Non Us | 110 | 105 | +4.8% |
| Other Eye Care · US | 138 | 123 | +12.2% |
| Other Neuroscience · Neuroscience | 46 | 56 | -17.9% |
| Other Neuroscience · Non Us | 4 | 2 | +100.0% |
| Other Neuroscience · US | 42 | 54 | -22.2% |
| Other Oncology · US | 11 | — | — |
| Ozurdex · Eye Care | 117 | 119 | -1.7% |
| Ozurdex · Non Us | 85 | 86 | -1.2% |
| Ozurdex · US | 32 | 33 | -3.0% |
| Qulipta · Neuroscience | 288 | 176 | +63.6% |
| Qulipta · Non Us | 36 | 8 | +350.0% |
| Qulipta · US | 252 | 168 | +50.0% |
| Rinvoq · Immunology | 2,184 | 1,614 | +35.3% |
| Rinvoq · Non Us | 625 | 444 | +40.8% |
| Rinvoq · US | 1,559 | 1,170 | +33.2% |
| Skyrizi · Immunology | 4,708 | 3,205 | +46.9% |
| Skyrizi · Non Us | 623 | 427 | +45.9% |
| Skyrizi · US | 4,085 | 2,778 | +47.0% |
| Ubrelvy · Neuroscience | 354 | 269 | +31.6% |
| Ubrelvy · Non Us | 10 | 8 | +25.0% |
| Ubrelvy · US | 344 | 261 | +31.8% |
| Venclexta · Non Us | 385 | 337 | +14.2% |
| Venclexta · Oncology | 726 | 677 | +7.2% |
| Venclexta · US | 341 | 340 | +0.3% |
| Vraylar · Neuroscience | 934 | 875 | +6.7% |
| Vraylar · Non Us | 3 | 2 | +50.0% |
| Vraylar · US | 931 | 873 | +6.6% |
| Vyalev · Neuroscience | 138 | 28 | +392.9% |
| Vyalev · Non Us | 85 | 28 | +203.6% |
| Vyalev · US | 53 | — | — |
| Interest Income | -72 | -129 | +44.2% |
| Comprehensive Income | 150 | 1,740 | -91.4% |
| Net Income Loss Available To Common Stockholders Basic | 176 | 1,551 | -88.7% |
| Interest Expense | 739 | 720 | +2.6% |
Balance Sheet
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 5,629 | 7,257 | -22.4% |
| Short-Term Investments | 42 | 28 | +50.0% |
| Accounts Receivable | 12,769 | 11,472 | +11.3% |
Show Counterparty Name breakouts |
|||
| Janssen Biotech Inc. · Collaborative Arrangement | 221 | 233 | -5.2% |
| Inventory | 4,938 | 4,450 | +11.0% |
| Prepaid Expense And Other Assets | 5,161 | 4,578 | +12.7% |
| Total Current Assets | 28,539 | 27,785 | +2.7% |
| Non-Current Assets | |||
| Long Term Investments | 291 | 267 | +9.0% |
| Property, Plant & Equipment | 5,483 | 5,141 | +6.7% |
| Goodwill | 35,626 | — | — |
| Other Non-Current Assets | 9,644 | 8,288 | +16.4% |
| Total Assets | 133,898 | 143,422 | -6.6% |
| Intangible Assets | 49,034 | 56,951 | -13.9% |
Show Product Lines breakouts |
|||
| Durysta · Developed Technology Rights | 711 | — | — |
| Resonic · Developed Technology Rights | 407 | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Developed Technology Rights | 47,874 | 54,998 | -13.0% |
| Licensing Agreements | 1,160 | 1,953 | -40.6% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 54,315 | 66,646 | -18.5% |
| Current Liabilities | |||
| Short Term Borrowings | 3,790 | — | — |
Show Short Term Debt Type breakouts |
|||
| Commercial Paper | 1.8 | — | — |
| Commercial Paper With Original Maturities Greater Than Three Months | 791 | — | — |
| Long Term Debt And Capital Lease Obligations Current | 1,982 | 12,570 | -84.2% |
| Accounts Payable And Accrued Liabilities Current | 33,619 | 30,492 | +10.3% |
Show Counterparty Name breakouts |
|||
| Janssen Biotech Inc. · Collaborative Arrangement | 217 | 282 | -23.0% |
| Total Current Liabilities | 39,391 | 43,062 | -8.5% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 2,480 | 2,749 | -9.8% |
| Other Non-Current Liabilities | 31,655 | 33,031 | -4.2% |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 62,971 | 58,509 | +7.6% |
| Minority Interest | 43 | 39 | +10.3% |
| Stockholders' Equity | |||
| Common Stock Value Outstanding | 18 | 18 | 0.0% |
| Treasury Stock Value | -9,143 | -7,848 | -16.5% |
| Additional Paid In Capital Common Stock | 22,291 | 21,160 | +5.3% |
| Retained Earnings | -14,234 | -4,964 | -186.7% |
| Accumulated Other Comprehensive Income | -1,574 | -2,334 | +32.6% |
| Total Stockholders' Equity | -2,642 | 6,032 | -143.8% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -2,599 | 6,071 | -142.8% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment Including Portion Attributable To Noncontrolling Interest | -659 | -1,473 | +55.3% |
| Accumulated Foreign Currency Adjustment Including Portion Attributable To Noncontrolling Interest | -625 | -1,085 | +42.4% |
| Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest | 131 | 198 | -33.8% |
| Accumulated Other Comprehensive Income | -1,574 | -2,334 | +32.6% |
| Additional Paid In Capital | 22,291 | 21,160 | +5.3% |
| Aoci Including Portion Attributable To Noncontrolling Interest | -1,574 | -2,334 | +32.6% |
| Common Stock | 18 | 18 | 0.0% |
| Net investment hedging activities | -421 | 26 | -1719.2% |
| Noncontrolling Interest | 43 | 39 | +10.3% |
| Retained Earnings | -14,234 | -4,964 | -186.7% |
| Treasury Stock Common | -9,143 | -7,848 | -16.5% |
| Total Liabilities & Equity | 133,898 | 143,422 | -6.6% |
Cash Flow Statement
| Metric | YTD Q3 2025 | YTD Q3 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation | 559 | 558 | +0.2% |
| Amortization Of Intangible Assets | 5,593 | 5,726 | -2.3% |
| Deferred Income Taxes | -107 | -682 | +84.3% |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | 5,089 | 3,492 | +45.7% |
| Payment For Contingent Consideration Liability Operating Activities | -2,184 | -1,456 | -50.0% |
| Stock-Based Compensation | 798 | 747 | +6.8% |
| Non Cash Litigation Reserve Adjustments Net Of Cash Payments | -1,069 | 341 | -413.5% |
| Impairment Of Intangible Assets Excluding Goodwill | 847 | — | — |
| Other Non-Cash Items | 6 | -75 | +108.0% |
| Change in Accounts Receivable | -1,652 | -180 | -817.8% |
| Change in Inventory | -209 | -191 | -9.4% |
| Change in Prepaid & Other Assets | -169 | 461 | -136.7% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | 1,549 | -1,070 | +244.8% |
| Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable | -1,408 | -1,405 | -0.2% |
| Net Cash from Operations | 13,812 | 11,758 | +17.5% |
| Investing Activities | |||
| Payments To Acquire Businesses Net Of Cash Acquired | -204 | -17,493 | +98.8% |
| Payments To Acquire Other Investments | -4,076 | -1,232 | -230.8% |
| Capital Expenditures | -885 | -683 | -29.6% |
| Payments To Acquire Marketable Securities | -29 | -46 | +37.0% |
| Proceeds From Sale Maturity And Collections Of Investments | 42 | 516 | -91.9% |
| Other Investing Activities | -28 | -8 | -250.0% |
| Net Cash from Investing | -5,180 | -18,946 | +72.7% |
| Financing Activities | |||
| Proceeds From Repayments Of Commercial Paper | 999 | — | — |
| Proceeds From Short Term Debt | 4,798 | 5,008 | -4.2% |
| Repayments Of Other Short Term Debt | -2,007 | -5,008 | +59.9% |
| Proceeds From Issuance Of Long Term Debt | 3,994 | 14,963 | -73.3% |
| Repayments Of Long Term Debt And Capital Securities | -6,789 | -3,851 | -76.3% |
| Debt Issuance Costs | -23 | -99 | +76.8% |
| Payments Of Dividends | -8,746 | -8,273 | -5.7% |
| Share Repurchases | -977 | -1,350 | +27.6% |
| Proceeds From Stock Options Exercised | 124 | 204 | -39.2% |
| Proceeds From Payments For Other Financing Activities | 69 | 56 | +23.2% |
| Net Cash from Financing | -8,558 | 1,650 | -618.7% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 31 | -19 | +263.2% |
| Net Change in Cash | 105 | -5,557 | +101.9% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 5,629 | 7,257 | -22.4% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.